RxDoctor Payments Data

Brad Herman, MD

Cardiovascular Disease · Fair Lawn, NJNPI 1760484729

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 95 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$478
  • Revance Therapeutics, Inc.$217
  • Amarin Pharma, Inc.$154
  • Kowa Pharmaceuticals America, Inc.$111
  • Boehringer Ingelheim$66
  • Esperion Therapeutics, Inc.$51
  • plus $224 from 10 others

What the payments were for

  • Food & beverage$1,23095%
  • Education$715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$531,178
Medicare patients
520
Services billed
15,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$184,718
OzempicSemaglutide81$89,080
XareltoRivaroxaban94$86,553
EntrestoSacubitril/Valsartan63$56,338
JardianceEmpagliflozin32$49,470
JanuviaSitagliptin Phosphate38$49,027
ProliaDenosumab14$23,875
VascepaIcosapent Ethyl16$10,422
Repatha SureclickEvolocumab12$9,610
BenicarOlmesartan Medoxomil16$8,236
BrilintaTicagrelor19$8,055
Olmesartan Medoxomil265$6,732
Breo ElliptaFluticasone/Vilanterol13$6,352
Rosuvastatin Calcium340$5,443
Atorvastatin Calcium324$3,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$89,08081 claims
Johnson & JohnsonXarelto$49$86,55394 claims
Boehringer IngelheimJardiance$66$49,47032 claims
MerckJanuvia$15$49,02738 claims
AmgenProlia$478$23,87514 claims
GSKBreo Ellipta$14$6,35213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Fair Lawn

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →